> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Fast Track for Surface Oncology Liver Cancer Drug
- URL: https://www.fdaweb.com/fda-fast-track-for-surface-oncology-liver-cancer-drug/
- Published: 2020-11-11T12:00:00.000Z
- Updated: 2026-09-14T16:35:57.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5148069

FDA has granted fast track designation for Surface Oncology’s SRF 388 for treating patients with hepatocellular carcinoma who have been previously treated with standard therapies such as vascular endothelial growth factor targeted agents and programmed death-ligand blockade.

The company [says](http://www.marketwatch.com/story/surface-oncology-announces-fda-fast-track-designation-granted-by-us-food-and-drug-administration-for-srf388-to-treat-liver-cancer-2020-11-11-7184025?ref=fdaweb.com) SRF 388 is enrolling patients with advanced solid tumors in a Phase 1 monotherapy dose-escalation study with planned expansions in liver and kidney cancer to further evaluate the agent as a monotherapy and in combination with other cancer therapies.

FDA previously gave SRF 388 orphan drug designation for treating hepatocellular carcinoma.